Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 4 Expression of metabolism-related proteins according to breast cancer phenotype a

From: Metabolic interaction between cancer cells and stromal cells according to breast cancer molecular subtype

Parameters Total Luminal A Luminal B HER2 TNBC P-value
(N= 740 ) (%) (n= 298 ) (%) (n= 166) (%) (n= 69) (%) (n= 207) (%)
Glut-1 in tumor       <0.001
 Negative 504 (68.1) 260 (87.2) 124 (74.7) 47 (68.1) 73 (35.3)  
 Positive 236 (31.9) 38 (12.8) 42 (25.3) 22 (31.9) 134 (64.7)  
Glut-1 in stroma       0.103
 Negative 724 (97.8) 296 (99.3) 162 (97.6) 66 (95.7) 200 (96.6)  
 Positive 16 (2.2) 2 (0.7) 4 (2.4) 3 (4.3) 7 (3.4)  
CAIX in tumor       0.008
 Negative 520 (70.3) 217 (72.8) 127 (76.5) 49 (71.0) 127 (61.3)  
 Positive 220 (29.7) 81 (27.2) 39 (23.5) 20 (29.0) 80 (38.6)  
CAIX in stroma       0.032
 Negative 627 (84.7) 264 (88.6) 137 (82.5) 52 (75.4) 174 (84.1)  
 Positive 113 (15.3) 34 (11.4) 29 (17.5) 17 (24.6) 33 (15.9)  
ATP synthase in tumor       0.027
 Negative 30 (4.1) 20 (6.7) 4 (2.4) 1 (1.4) 5 (2.4)  
 Positive 710 (95.9) 278 (93.3) 162 (97.6) 68 (98.6) 202 (97.6)  
ATP synthase in stroma       <0.001
 Negative 570 (77.0) 256 (85.9) 112 (67.5) 38 (55.1) 164 (79.2)  
 Positive 170 (23.0) 42 (14.1) 54 (32.5) 31 (44.9) 43 (20.8)  
Glutaminase in tumor       0.164
 Negative 219 (29.6) 85 (28.5) 60 (36.1) 21 (30.4) 53 (25.6)  
 Positive 521 (70.4) 213 (71.5) 106 (63.9) 48 (69.6) 154 (74.4)  
Glutaminase in stroma       0.001
 Negative 495 (66.9) 223 (74.8) 105 (63.3) 39 (56.5) 128 (61.8)  
 Positive 245 (33.1) 75 (25.2) 61 (36.7) 30 (43.5) 79 (38.2)  
BNIP3 in tumor       0.262
 Negative 504 (68.1) 206 (69.1) 112 (67.5) 40 (58.0) 146 (70.5)  
 Positive 236 (31.9) 92 (30.9) 54 (32.5) 29 (42.0) 61 (29.5)  
BNIP3 in stroma       0.262
 Negative 700 (94.6) 281 (94.3) 159 (95.8) 62 (89.9) 198 (95.7)  
 Positive 40 (5.4) 17 (5.7) 7 (4.2) 7 (10.1) 9 (4.3)  
MCT4 in tumor       <0.001
 Negative 540 (73.0) 253 (84.9) 118 (71.1) 49 (71.0) 120 (58.0)  
 Positive 200 (27.0) 45 (15.1) 48 (28.9) 20 (29.0) 87 (42.0)  
MCT4 in stroma       <0.001
 Negative 418 (56.5) 222 (74.5) 81 (48.8) 23 (33.3) 92 (44.4)  
 Positive 322 (43.5) 76 (25.5) 85 (51.2) 46 (66.7) 115 (55.6)  
Cytoplasmic Beclin-1       0.137
 Negative 406 (54.9) 169 (56.7) 99 (59.6) 31 (44.9) 107 (51.7)  
 Positive 334 (45.1) 129 (43.3) 67 (33.7) 38 (55.1) 100 (48.3)  
Nuclear Beclin-1       <0.001
 Negative 666 (90.0) 262 (87.9) 152 (91.6) 55 (79.7) 197 (95.2)  
 Positive 74 (10.0) 36 (12.1) 14 (8.4) 14 (20.3) 10 (4.8)  
LC3A in tumor       <0.001
 Negative 669 (90.4) 294 (98.7) 158 (95.2) 68 (98.6) 149 (72.0)  
 Positive 71 (9.6) 4 (1.3) 8 (4.8) 1 (1.4) 58 (28.0)  
LC3A in stroma       <0.001
 Negative 687 (92.8) 267 (89.6) 151 (91.0) 62 (89.9) 207 (100.0)  
 Positive 53 (7.2) 31 (10.4) 15 (9.0) 7 (10.1) 0 (0.0)  
LC3B in tumor       0.013
 Negative 475 (64.2) 186 (62.4) 124 (74.7) 42 (60.9) 123 (59.4)  
 Positive 265 (35.8) 112 (37.6) 42 (25.3) 27 (39.1) 84 (40.6)  
LC3B in stroma       0.645
 Negative 688 (93.0) 277 (93.0) 151 (91.0) 65 (94.2) 195 (94.2)  
 Positive 52 (7.0) 21 (7.0) 15 (9.0) 4 (5.8) 12 (5.8)  
Cytoplasmic p62 in tumor       <0.001
 Negative 274 (37.0) 131 (44.0) 51 (30.7) 15 (21.7) 77 (37.2)  
 Positive 466 (63.0) 167 (56.0) 115 (69.3) 54 (78.3) 130 (62.8)  
Nuclear p62 in tumor       <0.001
 Negative 532 (71.9) 180 (60.4) 131 (78.9) 44 (63.8) 177 (85.5)  
 Positive 208 (28.1) 118 (39.6) 35 (21.1) 25 (36.2) 30 (14.5)  
Nuclear p62 in stroma       0.876
 Negative 512 (69.2) 206 (69.1) 115 (69.3) 45 (65.2) 146 (70.5)  
 Positive 228 (30.8) 92 (30.9) 51 (30.7) 24 (34.8) 61 (29.5)  
  1. aBNIP3, BCL2/adenovirus E1B 19-kDa interacting protein 3; CAIX, carbonic anhydrase IX; Glut-1, glucose transporter 1; LC3A, microtubule-associated protein 1 light chain 3α; LC3B, microtubule-associated protein 1 light chain 3β; MCT4, monocarboxylate transporter 4; TNBC, triple-negative breast cancer.